Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 6/20 | 0.62 |
| ▸ | PPM1B | O75688 | 3/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.62 |
| ▸ | PPP1CC | P36873 | 3/20 | 0.62 |
| ▸ | PPP5C | P53041 | 2/20 | 0.62 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.62 |
| ▸ | NPY4R | P50391 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26377845 | 1.00 | TFPI2 (0.62) | TFPI2PPM1BPTPN1PPP1CCPPP5C | |
| SCHEMBL26377846 | 0.90 | TFPI2 (0.56) | TFPI2PPM1BPTPN1PPP1CCPPP5C | |
| SCHEMBL16731276 | 0.90 | TFPI2 (0.56) | TFPI2PPM1BPTPN1PPP1CCPPP5C | |
| SCHEMBL17585970 | 0.90 | TFPI2 (0.56) | TFPI2PPM1BPTPN1PPP1CCPPP5C | |
| SCHEMBL16731299 | 0.90 | TFPI2 (0.56) | TFPI2PPM1BPTPN1PPP1CCPPP5C | |
| SCHEMBL26378031 | 0.86 | PPM1B (0.60) | TFPI2PPM1BPTPN1PPP1CCPPP5C | |
| SCHEMBL18235532 | 0.85 | TFPI2 (0.59) | TFPI2PPM1BPTPN1PPP1CCPPP5C | |
| SCHEMBL26377839 | 0.83 | TFPI2 (0.60) | TFPI2PPM1BPTPN1PPP1CCPPP5C | |
| SCHEMBL18235540 | 0.83 | TFPI2 (0.60) | TFPI2PPM1BPTPN1PPP1CCPPP5C | |
| SCHEMBL21851614 | 0.83 | TFPI2 (0.56) | TFPI2PPM1BPTPN1PPP1CCPPP5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236102-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3736275-A1 | OXABICYCLOHEPTANE PRODRUGS FOR USE IN TREATING CANCER | Lixte Biotechnology, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200325151-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. | 2020-10-15 | — | — | US | disclosed |
| EP-3294287-B1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10364252-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9988394-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988394-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| WO-2016186963-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | LIXTE BIOTECHNOLOGY, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | LIXTE BIOTECHNOLOGY, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | LIXTE BIOTECHNOLOGY, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160074390-A1 | HUMAN DOSING OF PHOSPHATASE INHIBITOR | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| WO-2015196073-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015073802-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | LIXTE BIOTECHNOLOGY, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074390-A1 | HUMAN DOSING OF PHOSPHATASE INHIBITOR | PPM1A, PPP2R2A, PPM1B | TFPI2 2148/4885PPM1B 3/4885PTPN1 59/4885 |
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | OAT, OGG1, OTC | TFPI2 4233/4885PPM1B 1919/4885PTPN1 2495/4885 |
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | DUSP1, PPP5C, DUSP15 | TFPI2 320/4885PPM1B 42/4885PTPN1 85/4885 |
| US-20200325151-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | TFPI2 4843/4885PPM1B 1437/4885PTPN1 1462/4885 |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | TFPI2 4843/4885PPM1B 1437/4885PTPN1 1462/4885 |
| US-10364252-B2 | Oxabicycloheptane prodrugs | UGT2B7, UGT1A6, UGT1A1 | TFPI2 4843/4885PPM1B 1437/4885PTPN1 1462/4885 |
| US-11236102-B2 | Oxabicycloheptane prodrugs | UGT2B7, UGT1A6, UGT1A1 | TFPI2 4843/4885PPM1B 1437/4885PTPN1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.